New ibuprofen derivatives with thiazolidine-4-one scaffold with improved pharmaco-toxicological profile.
Acetic Acid
Analgesics
/ therapeutic use
Animals
Anti-Inflammatory Agents, Non-Steroidal
/ therapeutic use
Carrageenan
Cell Survival
/ drug effects
Edema
/ chemically induced
Hot Temperature
/ adverse effects
Ibuprofen
/ analogs & derivatives
Lethal Dose 50
Mice
Pain
/ chemically induced
Rats, Wistar
Thiazolidines
/ therapeutic use
Anti-inflammatory and analgesic effects
Ibuprofen
Thiazolidine-4-one
Toxicity degree
Journal
BMC pharmacology & toxicology
ISSN: 2050-6511
Titre abrégé: BMC Pharmacol Toxicol
Pays: England
ID NLM: 101590449
Informations de publication
Date de publication:
04 02 2021
04 02 2021
Historique:
received:
04
09
2020
accepted:
20
01
2021
entrez:
5
2
2021
pubmed:
6
2
2021
medline:
15
12
2021
Statut:
epublish
Résumé
Aryl-propionic acid derivatives with ibuprofen as representative drug are very important for therapy, being recommended especially for anti-inflammatory and analgesic effects. On other hand 1,3-thiazolidine-4-one scaffold is an important heterocycle, which is associated with different biological effects such as anti-inflammatory and analgesic, antioxidant, antiviral, antiproliferative, antimicrobial etc. The present study aimed to evaluated the toxicity degree and the anti-inflammatory and analgesic effects of new 1,3-thiazolidine-4-one derivatives of ibuprofen. For evaluation the toxicity degree, cell viability assay using MTT method and acute toxicity assay on rats were applied. The carrageenan-induced paw-edema in rat was used for evaluation of the anti-inflammatory effect while for analgesic effect the tail-flick test, as thermal nociception in rats and the writhing assay, as visceral pain in mice, were used. The toxicological screening, in terms of cytotoxicity and toxicity degree on mice, revealed that the ibuprofen derivatives (4a-n) are non-cytotoxic at 2 μg/ml. In addition, ibuprofen derivatives reduced carrageenan-induced paw edema in rats, for most of them the maximum effect was recorded at 4 h after administration which means they have medium action latency, similar to that of ibuprofen. Moreover, for compound 4d the effect was higher than that of ibuprofen, even after 24 h of administration. The analgesic effect evaluation highlighted that 4 h showed increased pain inhibition in reference to ibuprofen in thermal (tail-flick assay) and visceral (writhing assay) nociception models. The study revealed for ibuprofen derivatives, noted as 4 m, 4 k, 4e, 4d, a good anti-inflammatory and analgesic effect and also a safer profile compared with ibuprofen. These findings could suggest the promising potential use of them in the treatment of inflammatory pain conditions.
Sections du résumé
BACKGROUND
Aryl-propionic acid derivatives with ibuprofen as representative drug are very important for therapy, being recommended especially for anti-inflammatory and analgesic effects. On other hand 1,3-thiazolidine-4-one scaffold is an important heterocycle, which is associated with different biological effects such as anti-inflammatory and analgesic, antioxidant, antiviral, antiproliferative, antimicrobial etc. The present study aimed to evaluated the toxicity degree and the anti-inflammatory and analgesic effects of new 1,3-thiazolidine-4-one derivatives of ibuprofen.
METHODS
For evaluation the toxicity degree, cell viability assay using MTT method and acute toxicity assay on rats were applied. The carrageenan-induced paw-edema in rat was used for evaluation of the anti-inflammatory effect while for analgesic effect the tail-flick test, as thermal nociception in rats and the writhing assay, as visceral pain in mice, were used.
RESULTS
The toxicological screening, in terms of cytotoxicity and toxicity degree on mice, revealed that the ibuprofen derivatives (4a-n) are non-cytotoxic at 2 μg/ml. In addition, ibuprofen derivatives reduced carrageenan-induced paw edema in rats, for most of them the maximum effect was recorded at 4 h after administration which means they have medium action latency, similar to that of ibuprofen. Moreover, for compound 4d the effect was higher than that of ibuprofen, even after 24 h of administration. The analgesic effect evaluation highlighted that 4 h showed increased pain inhibition in reference to ibuprofen in thermal (tail-flick assay) and visceral (writhing assay) nociception models.
CONCLUSIONS
The study revealed for ibuprofen derivatives, noted as 4 m, 4 k, 4e, 4d, a good anti-inflammatory and analgesic effect and also a safer profile compared with ibuprofen. These findings could suggest the promising potential use of them in the treatment of inflammatory pain conditions.
Identifiants
pubmed: 33541432
doi: 10.1186/s40360-021-00475-0
pii: 10.1186/s40360-021-00475-0
pmc: PMC7863240
doi:
Substances chimiques
Analgesics
0
Anti-Inflammatory Agents, Non-Steroidal
0
Thiazolidines
0
Carrageenan
9000-07-1
Acetic Acid
Q40Q9N063P
Ibuprofen
WK2XYI10QM
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
10Subventions
Organisme : Agence Universitaire de la Francophonie
ID : 28/2019
Organisme : Universitatea de Medicina și Farmacie Grigore T. Popa - Iasi
ID : 23401/07.11.2018
Organisme : Universitatea de Medicina și Farmacie Grigore T. Popa - Iasi
ID : 30341/28.12.2017
Références
Surg Oncol. 2010 Sep;19(3):167-72
pubmed: 20022240
Pharmacol Rev. 2001 Dec;53(4):597-652
pubmed: 11734620
Cancer Manag Res. 2018 Oct 15;10:4631-4640
pubmed: 30410398
Mater Sci Eng C Mater Biol Appl. 2016 Dec 1;69:1318-27
pubmed: 27612832
Bioorg Chem. 2019 Aug;89:102993
pubmed: 31129500
Eur J Med Chem. 2018 Jun 10;153:56-64
pubmed: 29656890
J Exp Pharmacol. 2019 Aug 02;11:85-91
pubmed: 31447593
Aging Dis. 2018 Feb 1;9(1):143-150
pubmed: 29392089
Int Immunopharmacol. 2020 Nov;88:106893
pubmed: 32892073
Trop Life Sci Res. 2015 Apr;26(1):111-20
pubmed: 26868595
Arch Pharm Res. 2015 Apr;38(4):494-504
pubmed: 25173360
Sci Pharm. 2011 Jun;79(2):359-73
pubmed: 21773072
Int J Mol Sci. 2018 Apr 06;19(4):
pubmed: 29642417
Iran J Allergy Asthma Immunol. 2017 Feb;16(1):28-38
pubmed: 28417622
Bioorg Chem. 2017 Dec;75:406-423
pubmed: 29102723
Front Immunol. 2019 Mar 26;10:581
pubmed: 30972073
PLoS One. 2015 Aug 14;10(9):e0135558
pubmed: 26426535
Int J Mol Sci. 2012;13(2):1598-611
pubmed: 22408410
World J Virol. 2016 May 12;5(2):85-6
pubmed: 27175354
Pain. 2018 Apr;159(4):699-711
pubmed: 29251663
Molecules. 2014 Sep 18;19(9):15005-25
pubmed: 25237755
Pharmacol Biochem Behav. 2015 Apr;131:112-8
pubmed: 25687372
Eur J Pharmacol. 2018 Sep 5;834:54-64
pubmed: 30009814
Int J Biol Macromol. 2013 Jan;52:32-7
pubmed: 23036590
Bioorg Chem. 2019 Feb;82:86-99
pubmed: 30278282